Pregnancy is a time filled with excitement and joy. But for many expectant parents, there can also be serious health issues that put both the parent and the baby at risk. Conditions like preeclampsia and preterm birth can have serious consequences if not detected and treated early enough. Currently, doctors rely on a woman’s medical history and certain risk factors to determine her risk. However, these methods are not always accurate or precise.

But there’s hope on the horizon. Scientists are discovering that free-floating genetic material in a pregnant person’s blood, called cell-free RNA, could potentially be used to detect complications like preeclampsia and preterm birth. By analyzing the genes that are turned on or off during pregnancy, researchers can gain a dynamic view of the changes happening in the mother’s body. This could revolutionize our understanding of these complex conditions and enable earlier detection and treatment.

How It Works

During pregnancy, both the mother and the developing fetus release small fragments of genetic material into the bloodstream. These fragments, known as cell-free RNA, can be analyzed to gain insights into what’s happening in the body. For over a decade, doctors have been using cell-free DNA to screen for genetic abnormalities in the fetus. But RNA provides a more dynamic view of gene activity, allowing researchers to study changes that occur during pregnancy.

Researchers have been studying cell-free RNA in pregnant women’s blood to identify potential complications. They have found specific RNA patterns associated with conditions like preeclampsia and preterm birth. By analyzing the expression of genes in the blood, researchers have been able to predict the risk of developing these complications. In one study, a test based on 18 genes correctly identified all women who developed preeclampsia and accurately predicted most cases in a larger group of women.

The Road to the Clinic

While cell-free RNA tests for preeclampsia are leading the way, there is still much to learn. Researchers are working on understanding the underlying causes of the RNA changes associated with these complications. Additionally, it’s essential to determine the role of maternal versus fetal RNA in predicting the risk of complications.

Some tests are already being validated in large studies, and companies like Mirvie are working on bringing these tests to the clinic. However, questions remain about the benefits of these tests compared to existing screening methods and the best way to communicate test results to patients. It’s also important to consider the ethical implications and potential anxiety that these tests may cause for pregnant women.

Despite these challenges, researchers are optimistic about the future of cell-free RNA tests. They have already shown to be more accurate than current tests for preeclampsia, and they have the potential to provide personalized care for pregnant women. As we continue to see success in predicting and detecting complications, these tests could become an essential tool in ensuring the health and well-being of both parents and babies.